PCK1 Antibody Blocking Peptide

Regulates cataplerosis and anaplerosis， the processes that control the levels of metabolic intermediates in the citric acid cycle. At low glucose levels， it catalyzes the cataplerotic conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP)， the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. At high glucose levels， it catalyzes the anaplerotic conversion of phosphoenolpyruvate to oxaloacetate.